中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (6): 461-464.doi: 10.12144/zgmfskin202306461

• 综述 • 上一篇    下一篇

抗PD1/PD-L1免疫治疗诱发的大疱性类天疱疮的机制及诊疗进展

黄锐婷,姜福琼,胡龄予   

  1. 昆明医科大学第二附属医院，昆明，650101
  • 出版日期:2023-06-15 发布日期:2023-05-19

Update of diagnosis and treatment of bullous pemphigoid caused by anti-PD1/PD-L1

HUANG Ruiting, JIANG Fuqiong, HU Lingyu   

  1. Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China
  • Online:2023-06-15 Published:2023-05-19

PDF (PC)

76

摘要： 免疫检查点抑制剂(immune checkpoint inhibitors，ICPIs)是一种新型的抗肿瘤免疫治疗药物，其通过特异性结合T细胞表面抑制性受体而激活T细胞来清除癌细胞，获得较好的抗肿瘤效果。但治疗过程中会出现一系列免疫介导或免疫相关的不良反应，其中皮肤不良反应最常见。本文对免疫检查点抑制剂程序性死亡蛋白1(programmed cell death 1，PD-1)及其配体程序性死亡蛋白配体1(programmed cell death ligand 1，PD-L1)引起大疱性类天疱疮的文献进行回顾，综述了其患病率和发病机制、临床特征、诊断和治疗方法。

关键词: 类天疱疮,大疱性, PD-1抑制剂, PD-L1抑制剂, 免疫相关不良反应

Abstract: Immune checkpoint inhibitors (ICPIs) are a new type of anti-tumor immunotherapy drugs, which activate T cells to eliminate cancer cells by specifically binding to the inhibitory receptors on the surface of T cells, and obtain a good anti-tumor effect. However, a series of immune-mediated or immune-related adverse reactions may occur during the course of treatment, among which skin adverse reactions are the most common. In this paper, the literature of bullous pemphigoid caused by the immune checkpoint inhibitor programmed cell death 1(PD-1) and its ligand programmed cell death ligand 1 (PD-L1) were analyzed retrospectively. To review the prevalence rate, pathogenesis, clinical features, diagnosis and treatment methods.

Key words: pemphigoid, bullous, PD-1 inhibitor, PD-L1 inhibitor, immune-related adverse event